Regenerative Medical Technology Group Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7be61e67-c0c9-4ccc-a7f5-e9535cafed50/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $5.1M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-056841 |
| FY 2024 | $4.1M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-032016 |
| FY 2023 | $2.4M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-032991 |
| FY 2022 | $1.5M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-029942 |
| FY 2021 | $437.9k | 2021-01-01 – 2021-12-31 | evidence 0001213900-23-029942 |
| FY 2020 | $55.1k | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-021343 |
| FY 2019 | $30.1k | 2019-01-01 – 2019-12-31 | evidence 0001213900-20-041866 |
| FY 2018 | $50.1k | 2018-01-01 – 2018-12-31 | evidence 0001213900-19-006566 |
| FY 2017 | $29.2k | 2017-01-01 – 2017-12-31 | evidence 0001213900-19-006566 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Regenerative Medical Technology Group Inc. — all facts · Net Income · Operating Income